SCHEMBL2677873

SCHEMBL2677873

CCN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(S(=O)(=O)c3cc(F)cc(F)c3)CC4(C)C)c(C(N)=O)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 4/20 0.49
NTRK1 P04629 10/20 0.44
NTRK3 Q16288 5/20 0.44
NTRK2 Q16620 4/20 0.44
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
CCNA1 P78396 3/20 0.41
ALK Q9UM73 3/20 0.39
INSR P06213 2/20 0.39
PRKCB P05771 2/20 0.38
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNE1 P24864 1/20 0.37
GSK3B P49841 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
PLK4 O00444 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKCG P05129 1/20 0.37
ROS1 P08922 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677591 0.93 IGF1R (0.58) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL2677876 0.92 IGF1R (0.50) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL2678530 0.91 NTRK1 (0.51) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL2678941 0.87 IGF1R (0.52) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL2678319 0.87 IGF1R (0.66) IGF1RNTRK1NTRK3NTRK2ALK
SCHEMBL2679435 0.87 IGF1R (0.52) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL1891894 0.86 IGF1R (0.47) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL1885378 0.85 INSR (0.52) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL2678625 0.85 NTRK1 (0.42) IGF1RNTRK1NTRK3NTRK2ALK
SCHEMBL2678352 0.85 NTRK1 (0.46) IGF1RNTRK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885NTRK1 1131/4885NTRK3 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.